Form 8-K - Current report:
SEC Accession No. 0001437749-22-007848
Filing Date
2022-03-31
Accepted
2022-03-31 16:05:58
Documents
15
Period of Report
2022-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K arav20220316_8k.htm   iXBRL 8-K 24496
2 EXHIBIT 99.1 ex_347950.htm EX-99.1 87107
7 logo.jpg GRAPHIC 2818
  Complete submission text file 0001437749-22-007848.txt   263471

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA arav-20220331.xsd EX-101.SCH 3602
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE arav-20220331_def.xml EX-101.DEF 11920
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE arav-20220331_lab.xml EX-101.LAB 15967
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE arav-20220331_pre.xml EX-101.PRE 12131
9 EXTRACTED XBRL INSTANCE DOCUMENT arav20220316_8k_htm.xml XML 2655
Mailing Address RIVER OAKS TOWER 3730 KIRBY DRIVE, SUITE 1200 HOUSTON TX 77098
Business Address RIVER OAKS TOWER 3730 KIRBY DRIVE, SUITE 1200 HOUSTON TX 77098 936-355-1910
Aravive, Inc. (Filer) CIK: 0001513818 (see all company filings)

EIN.: 264106690 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36361 | Film No.: 22792414
SIC: 2834 Pharmaceutical Preparations